UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

Supplies of the heartburn drug ranitidine have been recalled globally ... Ranitidine is known in some cases under the brand name Zantac and is used to prevent and relieve heartburn associated ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

So why would GSK, the largest of the four major distributors of the now-recalled stomach acid drug, suddenly abandon the tried-and-true defense mantra, “millions for defense, not a penny for tribute”?

Quinidine sulfate 300mg; ext-rel tabs. Complete AV or bundle branch block or other severe intraventricular conduction defects. Myasthenia gravis. Arrhythmias due to digitalis intoxication.

The British drugmaker’s settlement with 10 separate law firms resolves 93% of all U.S. cases currently filed against GSK over claims its popular Zantac drug contained the carcinogen N ...

has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer, although GSK says ...

Supplies of the heartburn drug ranitidine have been recalled globally ... Ranitidine is known in some cases under the brand name Zantac and is used to prevent and relieve heartburn associated ...

(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced ...